Can a liver cancer drug stop eye cancer spread?
NCT ID NCT02517736
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug sorafenib (Nexavar) in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is already used for other cancers, and researchers wanted to know if it could help people with this rare eye cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sorafenib (Nexavar)
- What this could lead to
- If it works, this could provide a treatment option to slow tumor growth in patients with metastatic uveal melanoma.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply broadly. Sorafenib can cause side effects like fatigue, diarrhea, and skin reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service d'ophtalmologie, CHU de Caen
Caen, 14000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- Can a pill prevent eye cancer spread? new trial aims to find out
- New drug shows promise in shrinking eye cancer before surgery